Clinical Trial Update: Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of Infancy [Phase 4]

View source ↗

Summary

Phase 4 trial update on lanreotide Autogel for congenital hyperinsulinism of infancy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Hyperinsulinism

Drugs mentioned

• Lanreotide Autogel (lanreotide)

Snippet

Sponsor: Sheba Medical Center | Conditions: Congenital Hyperinsulinism | Phase 4 | Status: COMPLETED